专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

161. 发明公开

KR1020090088874A 인터루킨-6에 대한 결합 구성원 有权
标题翻译： INTERLEUKIN-6的绑定会员
公开(公告)号：KR1020090088874A
公开(公告)日：2009-08-20
申请号：KR1020097009354
申请日：2007-11-28
申请人： 아스트라제네카 아베 , 메디뮨 리미티드
发明人： 말린더필립 , 레인스티븐가드프레이 , 크루위스시몬찰스
IPC分类号： C07K16/24 , C12N15/13 , A61K39/395 , A61P35/00
CPC分类号： C07K16/248 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/6857 , G01N2333/5412
摘要： Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6. ® KIPO & WIPO 2009
摘要翻译：绑定构件，例如人类抗体分子，其结合白细胞介素-6（IL-6）并中和其生物学效应。在医疗中使用IL-6的结合成员，例如用于治疗与IL-6相关的炎性疾病和肿瘤。 ®KIPO＆WIPO 2009

162. 发明公开

KR1020090058518A ＥＧＦＲ 에 결합하는 항원 결합 분자, 이를 암호화하는 벡터, 및 그의 용도 有权
标题翻译：抗体结合分子EGFR，载体编码它们及其用途
公开(公告)号：KR1020090058518A
公开(公告)日：2009-06-09
申请号：KR1020097004840
申请日：2007-08-09
申请人： 로슈 글리카트 아게
发明人： 우마나파블로 , 모쓰너에케하르트
IPC分类号： C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
CPC分类号： C07K16/464 , C07K16/2863 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/72 , C07K2317/732
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
摘要翻译：本发明涉及抗原结合分子（ABM）。在具体实施方案中，本发明涉及重组单克隆抗体，包括对人EGFR特异的嵌合，灵长类或人源化抗体。此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

163. 发明公开

KR1020090027227A 항-ＤＬＬ4 항체 및 이의 사용 방법 无效
标题翻译： ANTI-DLL4抗体及其使用方法
公开(公告)号：KR1020090027227A
公开(公告)日：2009-03-16
申请号：KR1020087032160
申请日：2007-06-06
申请人： 제넨테크, 인크.
发明人： 얀,민홍 , 유,얀
IPC分类号： C07K16/22 , C12N15/13 , A61K39/395 , A61P35/00
CPC分类号： A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要： The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies.
摘要翻译：本发明提供抗DLL4抗体，以及包含使用这些抗体的组合物。

164. 发明公开

KR1020090013745A 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물 有权
标题翻译：用于治疗肿瘤和相关产品的抗MET单克隆抗体，片段和载体
公开(公告)号：KR1020090013745A
公开(公告)日：2009-02-05
申请号：KR1020087016543
申请日：2007-02-05
申请人： 메테레시스 트랜스레이셔날 리서치 에스.에이.
发明人： 코모글리오,파올로마리아 , 비그나,엘리 , 지오다노,실비
IPC分类号： C07K16/28 , C12N15/13 , C12N15/867 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/32 , C07K2317/76 , C07K2317/77 , C12N2799/027
摘要： Use of a monoclonal antibody directed against the extracellular domain of hepatocyte growth factor is disclosed for the preparation of a medicament for the treatment of tumors and/or metastases and of a diagnostic tool for detecting neoplastic cells as well as vectors comprising at least a portion of the nucleotide sequence encoding the anti-Met monoclonal antibody, products containing the anti-Met monoclonal antibody and/or at least one fragment thereof and at least one kinase inhibitor.
摘要翻译：公开了针对肝细胞生长因子的细胞外结构域的单克隆抗体的用途，用于制备用于治疗肿瘤和/或转移的药物和用于检测肿瘤细胞的诊断工具以及包含至少一部分编码抗Met单克隆抗体的核苷酸序列，含有抗Met单克隆抗体的产物和/或其至少一个片段和至少一种激酶抑制剂。

165. 发明公开

KR1020080090418A 알레르기 질병 치료를 위한 흉선 간질 림포포이에틴수용체에 대한 항체 有权
标题翻译：抗结核性淋巴细胞白血病受体用于治疗过敏性疾病的抗体
公开(公告)号：KR1020080090418A
公开(公告)日：2008-10-08
申请号：KR1020087016912
申请日：2007-01-11
申请人： 아이알엠 엘엘씨
发明人： 둥,리췬 , 나소프,마르크
IPC分类号： C07K16/28 , C12N15/13 , A61K39/00
CPC分类号： C07K16/28 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
摘要翻译：在本发明中公开的是特异性识别和拮抗人TSLP受体的抗体，以及使用这些抗体治疗或改善由TSLP信号转导介导的疾病或病症的方法。

166. 发明授权

KR100852742B1 ＰＧＰ9．5 유전자 프로모터의 메틸화와 관련된 암 진단용조성물 및 그 용도 有权
标题翻译：用于检测与PGP9.5基因启动子甲基化相关的癌症的组合物及其用途
公开(公告)号：KR100852742B1
公开(公告)日：2008-08-18
申请号：KR1020070016789
申请日：2007-02-16
申请人： 경북대학교 산학협력단
发明人： 김동선 , 김상걸
IPC分类号： C12N15/13 , C12N15/09
摘要： A composition comprising non-methylated CpG islands of a PGP9.5 gene promoter is provided to be used to diagnose cancer since the methylation of the PGP9.5 gene influences on the expression of the PGP9.5 in cancer cells. A composition for diagnosing cancer such as gallbladder carcinoma, non-small cell lung cancer, invasive colorectal cancer and esophageal squamous cell carcinoma includes a polynucleotide sequence consisting of a sequence of SEQ ID : NO. 1, wherein bases from 131st to 329th of the SEQ ID : NO. 1 consist of non-methylated bases. A genetic marker for diagnosing the cancer consists of 198-496 numbers of a consecutive base sequence including the bases from 131st to 329th of the SEQ ID : NO. 1. A method for detecting methylation of a PGP9.5 gene promoter comprises the steps of: (a) obtaining a sample from an individual; (b) obtaining a genome DNA from the sample; (c) treating the genome DNA with a compound capable of deforming a cytosine base or a methylation sensitive restriction enzyme; (d) amplifying the treated DNA using a primer pair consisting of SEQ ID : NOs. 4 and 5 or 6 and 7 capable of amplifying CpG islands of the PGP9.5 gene promoter; and (e) identifying the existence of an amplified product. A kit for diagnosing the cancer comprises a primer for MSP(methylation specific PCR) consisting of a primer pair of SEQ ID : NOs. 4 and 5 as an effective ingredient.
摘要翻译：提供包含PGP9.5基因启动子的非甲基化CpG岛的组合物用于诊断癌症，因为PGP9.5基因的甲基化影响癌细胞中PGP9.5的表达。用于诊断癌症的组合物，例如胆囊癌，非小细胞肺癌，侵袭性结肠直肠癌和食管鳞状细胞癌包括由SEQ ID NO：1所示的序列组成的多核苷酸序列。 1，其中SEQ ID NO：1的第131至329位的碱基。 1由非甲基化碱基组成。用于诊断癌症的遗传标记物包括连续碱基序列的198-496个数目，包括SEQ ID NO：131的第131位至第329位的碱基。 1.一种检测PGP9.5基因启动子甲基化的方法，包括以下步骤：（a）从个体获得样品; （b）从样品中获得基因组DNA; （c）用能够使胞嘧啶碱基或甲基化敏感性限制酶变形的化合物处理基因组DNA; （d）使用由SEQ ID NO：构成的引物对扩增处理的DNA。 4和5或6和7能够扩增PGP9.5基因启动子的CpG岛; 和（e）鉴定扩增产物的存在。用于诊断癌症的试剂盒包括由引物对SEQ ID NO：组成的用于MSP的引物（甲基化特异性PCR）。 4和5作为有效成分。

167. 发明公开

KR1020080059379A 종양 괴사 인자（ＴＮＦ）-관련 세포사멸-유도성리간드 수용체 2 폴리펩티드 및 항체 失效
标题翻译： TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES
公开(公告)号：KR1020080059379A
公开(公告)日：2008-06-27
申请号：KR1020087006831
申请日：2006-08-28
申请人： 암젠 인코포레이티드
发明人： 글리니아크브라이언 , 양지아오-동 , 웅-매든샤론 , 폴츠이안 , 펭지아오 , 피치앨리슨 , 포스터스티븐 , 케쳄랜들알
IPC分类号： C07K16/28 , A61K39/00 , C12N15/13
CPC分类号： A61K39/39558 , A61K38/00 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C07K2317/92
摘要： Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand ("TRAIL") Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
摘要翻译：提供多肽。提供结合这些多肽的抗体或抗原结合结构域。还提供了获得结合肿瘤坏死因子（TNF）相关的凋亡诱导配体（“TRAIL”）受体-2（TR-2）的抗体的方法，包括向动物施用至少一种这样的多肽并获得抗体其结合来自动物的TR-2。提供与TR-2反应的抗体。还提供产生与TR-2反应的抗体的细胞，包含与TR-2反应的抗体的药物组合物，使用与TR-2反应的抗体的方法，以及包含与TR-2反应的抗体的试剂盒。还提供了通过施用这样的多肽来降低或预防抗体与TR-2结合的方法。

168. 发明授权

KR100835786B1 ＩＬ-１７Ａ／Ｆ 이종 폴리펩티드 및 그의 치료 용도 有权
标题翻译： IL-17A / F异源多肽及其治疗方法
公开(公告)号：KR100835786B1
公开(公告)日：2008-06-09
申请号：KR1020067000410
申请日：2004-06-02
申请人： 제넨테크, 인크.
发明人： 아르노트,데이비드 , 구르니,오스틴 , 하스,필립 , 리,제임스 , 후,얀
IPC分类号： C07K14/54 , C12N15/13 , A61K38/17 , C12P21/02
CPC分类号： C07K16/244 , A61K38/00 , C07K14/54 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/76 , G01N33/6869 , Y02A50/463 , Y02A50/473
摘要： 본 발명은 본원에서 인터루킨 17A/F (IL-17A/F)로 지칭되는 인터루킨-17 및 인터루킨-17F의 이종이량체로 구성된 신규한 자연 발생 인간 사이토카인에 관한 것이다. 또한, 본 발명은 상기 핵산 서열을 포함하는 벡터 및 숙주 세포, 이종 폴리펩티드 서열에 융합된 본 발명의 폴리펩티드를 포함하는 키메라 폴리펩티드 분자, 본 발명의 폴리펩티드에 결합하는 특이적인 항체, 및 본 발명의 폴리펩티드를 제조하는 방법을 제공한다. 또한, 본 발명은 퇴행성 연골 장애 및 다른 염증성 질환을 치료하는 방법을 제공한다.
사이토카인, 인터루킨 17A/F, 퇴행성 연골 장애, 염증성 질환
摘要翻译：本发明涉及一种新型天然存在的人类细胞因子，其由本文称为白细胞介素17A / F（IL-17A / F）的白细胞介素-17和白细胞介素-17F的异源二聚体组成。本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异质多肽序列融合的本发明多肽的嵌合多肽分子，与本发明的多肽结合的特异性抗体以及制备本发明多肽的方法本发明。本文还提供了治疗退行性软骨疾病和其它炎性疾病的方法。

169. 发明公开

KR1020070115996A 항체 无效
标题翻译：抗体
公开(公告)号：KR1020070115996A
公开(公告)日：2007-12-06
申请号：KR1020077021792
申请日：2006-02-20
申请人： 헬레닉 파스퇴르 인스티튜트
发明人： 마마라키,아브기 , 벨리메지,마리아 , 파파나스타셔우,다나이 , 멀코리,에프로씨니 , 바세바니스,콘스탄티노
IPC分类号： C07K16/32 , C12N15/13 , C12N15/70 , C12N1/21
CPC分类号： C07K16/32 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/77 , C07K2317/82
摘要： The present invention describes an isolated antibody or a fragment, variant or derivative thereof, capable of specifically binding to Her2/neu comprising a heavy chain variable domain wherein said heavy chain variable domain comprises an amino acid sequence as set out in at least one of SEQ ID NOs: 1, 2 or 3 or a sequence having at least 75% identity (homology) thereto or a functional fragment thereof as well as nucleic acid sequences encoding the same and methods for their production. The invention also relates to a method for the treatment of Her2/neu expressing cancer in a patient comprising administering to the patient in need of such treatment a therapeutically effective amount of any of those antibody, polypeptide or nucleic acid molecules described herein.
摘要翻译：本发明描述了能够特异性结合Her2 / neu的分离的抗体或其片段，变体或衍生物，其包含重链可变结构域，其中所述重链可变结构域包含SEQ ID NO：1中至少一个所示的氨基酸序列 ID NO：1,2或3或与其具有至少75％同一性（同源性）或其功能片段的序列以及编码其的核酸序列及其制备方法。本发明还涉及用于治疗患者中Her2 / neu表达癌症的方法，包括向需要这种治疗的患者施用治疗有效量的本文所述的那些抗体，多肽或核酸分子中的任何一种。

170. 发明公开

KR1020070009581A 종양 및 전이성 질환 치료 방법 및 조성물 无效
标题翻译：用于治疗肿瘤和分化疾病的方法和组合物
公开(公告)号：KR1020070009581A
公开(公告)日：2007-01-18
申请号：KR1020067018079
申请日：2005-02-03
申请人： 엘란 파마슈티컬스, 엘엘씨
发明人： 베너,낸시
IPC分类号： A61K39/395 , A61K31/541 , C12N15/13 , A61P35/00
CPC分类号： C07K16/2839 , A61K31/381 , A61K2039/505 , C07K16/2842 , C07K2317/73
摘要： Compositions, methods, and combination therapies for the treatment of lymphomas, leukemias, melanomas, prostate cancer, and metastatic disease are provided. Specifically, compositions comprising anti-alpha4 integrin immunoglobulins or immunoglobulins that bind to an alpha4 integrin ligand (e.g., MadCAM-1 and VCAM-1) are disclosed for use in inhibiting tumor growth and progression and inhibition of metastases. A preferred immunoglobulin for use in treating tumors and metastases is natalizumab. The compositions and methods using these immunoglobulins can be used alone or in combination with other reagents and cancer treatment modalities. ® KIPO & WIPO 2007
摘要翻译：提供了用于治疗淋巴瘤，白血病，黑素瘤，前列腺癌和转移性疾病的组合物，方法和组合疗法。具体地，公开了包含结合于α4整联蛋白配体（例如MadCAM-1和VCAM-1）的抗α4整联蛋白免疫球蛋白或免疫球蛋白的组合物用于抑制肿瘤生长和进展以及转移的抑制。用于治疗肿瘤和转移瘤的优选免疫球蛋白是那他珠单抗。使用这些免疫球蛋白的组合物和方法可以单独使用或与其它试剂和癌症治疗方式组合使用。 ®KIPO＆WIPO 2007

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式